



1632

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

09/806,110

Filing Date

08/31/2001

First Named Inventor

Karaplis et al.

Group Art Unit

1632

Examiner Name

Unknown

Attorney Docket Number

109647.121

Total Number of Pages in This Submission

ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment / Reply

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/ Incomplete Application

☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

☐ Assignment Papers (for an Application)

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) _____

☐ After Allowance Communication to Group

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please identify below):

- Postcard

Remarks

1. Form PTO-1449
2. 9 Publications

RECEIVED

MAR 06 2003

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Ann-Louise Kerner, Ph.D., Reg. No. 33,523

Signature

Ann-Louise Kerner

Date

02/28/2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 02/28/2003

Typed or printed name

Ti na M. Dougal


Signature

Tina M. Dougal

Date

02/28/2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

MAR 06 2003

PATENT

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Andrew C. Karaplis, et al.
Serial No.: 09/806,110
Filed: August 31, 2001
For: USE OF PEX IN THE TREATMENT OF METABOLIC BONE DISEASES

Examiner: Unknown

Group Art Unit: 1632

Attorney Docket No.: 109647.121/SWA-011US

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being filed as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on February 28, 2003.

Tina M. Dougal
Tina M. Dougal

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97-98, Applicants bring to the attention of the Examiner the following publications listed on the attached Form PTO-1449.


This submission does not constitute a representation by Applicants that a search has been made or that no better art exists and does not constitute an admission that any of the listed publications are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed publications, should one or more of the publications be applied against the claims of the present application.

Copies of the publications listed on the attached Form PTO-1449 are submitted herewith. It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449 with the next Patent Office communication.

As this Information Disclosure Statement is being filed prior to the mailing of the first Office Action on the merits and is therefore submitted as both timely and proper; thus, no fees are believed to be due. However, in the event of a fee deficiency, the Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 08-0219.

Respectfully submitted,

Dated: February 28, 2003



Ann-Louise Kerner, Ph.D.
Registration No. 33,523
Attorney for Applicants

Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Tel: (617) 526-6192
Fax: (617) 526-5000

Subt. For, PTO-1449

INFORMATION DISCLOSURE IN AN APPLICATION

(Use several sheets if necessary)

Docket Number
109647.121/SWA-11

Application Number
09/806,110

Applicant
Karaplis et al.

Filing Date
August 31, 2001

Group Art Unit
1632

Sheet	1	OF	1
-------	---	----	---

U.S. Patent Documents

[illegible]

Foreign Patent Documents

Foreign Patent Documents						TRANSLATION	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	WO 98/10078	03/12/98	WO				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

	A1	Du, L., et al. (1996) <i>Genomics</i> 36 , 22-28
	A2	The HYP Consortium (1995) <i>Nature Genetics</i> 11 , 13-136
	A3	Beck, L. et al. (1997) <i>J. Clin. Invest.</i> 99 , 1200-1209
	A4	Grieff, M. et al. (1997) <i>Biochem. Biophys. Res. Commun.</i> 231 , 635-639
	A5	Guo, R. and Quarles, L.D. (1997) <i>J. Bone Miner. Res.</i> 12 , 1009-1017
	A6	Lipman, M. et al., "Cloning of Human PEX cDNA: Expression, subcellular localization, and endopeptidase activity", <i>Journal of Biological Chemistry</i> , May 29, 1998, Vol. 273 , No. 22 , pp. 13729-13737
	A7	Schneider, H.G. et al. "Parathyroid Hormone-Related Protein mRNA and Protein Expression in Multiple Myeloma: A Case Report", <i>Journal of Bone and Mineral Research</i> , Oct. 1998, Vol. 12 , No. 10 , pp. 1640-1643
	A8	Guisse, T. A. et al. "Evidence for a Causal Role of Parathyroid Hormone-related Protein in the Pathogenesis of Human Breast Cancer-mediated Osteolysis", <i>The American Society for Clinical Investigation, Inc.</i> , October 1996, Vol. 98 , No. 7 , pp. 1544-1549
	A9	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.